Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-Infected Patients in Taiwan.
Phase of Trial: Phase IV
Latest Information Update: 15 Sep 2009
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 09 Dec 2008 Status changed from recruiting to completed.
- 04 Nov 2008 Results presented at AASLD
- 04 Nov 2008 Primary endpoint 'Sustained virological response rate' has been met.